Milestone Pharmaceuticals and Astria Therapeutics in the spotlight

Deep-dive fundamental and technical analysis of $MIST and $ATXS

The biotech market saw the total EV of publicly traded companies continue to rise in the start of July, up by about 25% from the mid-June lows. Although fundamentals are slowly improving, the macro environment & continued rising interest rates remain a question mark as we kick-off the second half of the year.

Below are two names that we are paying attent…